• Bulletin of the Korean Chemical Society
• /
• 제33권8호
• /
• pp.2546-2552
• /
• 2012

A novel biguanide-functionalized $Fe_3O_4/SiO_2$ magnetite nanoparticle with a core-shell structure was developed for utilization as a heterogeneous organosuperbase in chemical transformations. The structural, surface, and magnetic characteristics of the nanosized catalyst were investigated by various techniques such as transmission electron microscopy (TEM), powder X-ray diffraction (XRD), vibrating sample magnetometry (VSM), elemental analyzer (EA), thermogravimetric analysis (TGA), $N_2$ adsorption-desorption (BET and BJH) and FT-IR. The biguanide-functionalized $Fe_3O_4/SiO_2$ nanoparticles showed a superpara-magnetic property with a saturation magnetization value of 46.7 emu/g, indicating great potential for application in magnetically separation technologies. In application point of view, the prepared catalyst was found to act as an efficient recoverable nanocatalyst in nitroaldol and domino Knoevenagel condensation/Michael addition/cyclization reactions in aqueous media under mild condition. Additionally, the catalyst was reused six times without significant degradation in catalytic activity and performance.

• 한국의류산업학회지
• /
• 제7권1호
• /
• pp.81-84
• /
• 2005

Skin patch test and antibacterial properties of the reaction products between poly(hexamethyl biguanide) hydrochloride and trimethylol melamine on textile fabrics were examined. Antibacterial activities of anti-microbial agent treated samples are very good. The reduction ratios against four kinds of colonies are 99.9 % after repeated laundering ten times. Skin patch test results for anti-microbial agent treated samples are almost-negative by Hi-scope judgement and macroscopical judgement.

• Bulletin of the Korean Chemical Society
• /
• 제33권11호
• /
• pp.3640-3644
• /
• 2012

An efficient synthetic method for direct Henry reaction catalyzed by a biguanide; namely metformin, as an organosuper-base, between a variety of aromatic and aliphatic aldehydes and nitromethane under neat conditions has been developed. Convenient procedure for removal of the catalyst, chemoselective acquiring of ${\beta}$-nitroalcohols as predominant products, as far as possible short reaction time with excellent conversions are advantages of the developed protocol.

• 대한시과학회지
• /
• 제20권4호
• /
• pp.531-541
• /
• 2018

목적 : 항균제 polyhexamethylene Biguanide(PHMB), epigallocatechin gallate(EGCG) 및 PHMB/EGCG 혼합물의 각막상피세포(primary human corneal epithelial cells, HCEpiCs)에 대한 급성독성을 평가하고자 하였다. 방법 : 각막상피세포를 0.00001~0.005% PHMB, 0.001~5% EGCG 및 0.00005% PHMB/0.05% EGCG 혼합물이 각각 포함된 배양액에서 30분, 60분, 120분 및 240분 동안 배양하였다. 배양한 각막상피세포를 고정한 다음 Draq 5로 염색하고 공초점현미경과 ImageXpress $Ultra^{TM}$를 이용하여 세포형태를 관찰하여 세포생존율과 세포자살(apoptosis)을 비교하였다. 결과 : 배양된 각막상피세포는 0.00005% 이하의 PHMB 농도 및 0.05% 이하의 EGCG 농도에서는 세포 독성이 나타나지 않았다. 0.00005% PHMB/0.05% EGCG 혼합물이 포함된 배양액에서 급성 세포독성은 관찰되지 않았으나 240분 배양시킨 경우에는 손상된 각막상피세포 수가 증가하고 생존 세포의 수는 감소하였다. 결론 : 항균 시너지 효과를 갖는다고 보고된 0.00005% PHMB/0.05% EGCG 혼합물의 경우 각막상피세포에 대한 급성독성은 없었으나 만성효과에 대해서는 추가적인 연구가 필요할 것으로 생각된다.

• Parasites, Hosts and Diseases
• /
• 제44권4호
• /
• pp.313-320
• /
• 2006

In an effort to characterize, on the molecular scale, the Acanthamoeba initially isolated from the cornea of an amoebic keratitis patient associated with overnight-wear orthokeratology lens in Korea, we conducted mitochondrial DNA restriction fragment length polymorphism, 18S rDNA sequencing, and drug sensitivity analyses on the isolate (KA/PE1). The patient was treated with polyhexamethylene biguanide, chlorhexidine and oral itraconazole, which resulted in resolution of the patient's ocular inflammation. The majority of the molecular characteristics of the KA/PE1 were determined to be identical, or quite similar, to those of A. castellanii Ma strain, which had been isolated also from amoebic keratitis. The risk of Acanthamoeba keratitis as a potential complication of overnight orthokeratology is briefly discussed.

• Parasites, Hosts and Diseases
• /
• 제36권1호
• /
• pp.7-14
• /
• 1998

최근 가시아메바 각막염의 치료제로 새롭게 주목을 받고 있는 polyhexamethylene biguanide (PHMB)의 가시아메바에 대한 작용 기전을 알기 위해 각막염 유래 가시아메바 4 분리주에 대한 PHMB의 최저 살충 농도 (minimal cysticidal concentration; MCC)를 결정하고, 이 MCC의 PHMB로 처리한 포낭의 형태학적 변화를 투과전자현미경으로 관찰하였다. PHMB의 8시간과 48시간에 대한 MCC를 결정하였는데, 8시간 MCC는 KA/E1 $14.32{\;}{\mu\textrm{g}}/ml$. KA/E2 $22.45{\;}{\mu\textrm{g}}/ml$, KA/E3 $21.54{\;}{\mu\textrm{g}}/ml$, 및 KA/E4 $23.59{\;} {\mu\textrm{g}}/ml$였다. 48시간 MCC는 KA/El $3.97{\;}{\mu\textrm{g}}/ml$, KA/E2 $7.49{\;}{\mu\textrm{g}}/ml$, KA/E3 $6.40{\;}{\mu\textrm{g}}/ml$ 및 KA/E4 $4.92{\mu\textrm{g}}/ml$로 나타났다. PHMB를 처리한 포낭에서는 포낭 내 amoeb고가 심하게 수축되고 이로 인해 포낭 내벽과 분리되는 형태학적 변화가 관찰되었다. 세포막 아래의 subplasmalemmal lipid droplet의 모양이 불규칙해졌다 심한 경우 세포질이 응집되고. 미토콘드리아의 cristae도 크게 감소하는 등 세포 내 소기관들도 모양이 심하게 변하였다. 포낭 내외벽은 그 형태가 비교적 잘 유지되었다. 이상의 변화들로 볼 때. PHMB는 세포막에 주로 작용하며, 세포 내 소기관들의 막에도 영향을 미치는 것을 알 수 있었다 가시아메바의 세포막의 lipidcomposition은 아직 잘 알려져 있지 않지만 PHMB에 의한 가시아메바 포낭에 대한 살충 효과는 environmental biocide로서 Escherichia col거 세포벽에 있는 acidic prlospholipids에 작용하여 살균 효과를 나타내는 것과 유사한 기전으로 일어날 것으로 사료된다.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.1
• /
• pp.307.1-307.1
• /
• 2003

Metfotrmin is a biguanide antihyperglycemic agent often used for the treatment of non-insulin dependent diabetics(NIDDM). Metformin lowers both fasting and postprandial plasma glucose concentrations by improving insulin sensitivity at hepatic and peripheral tissues. The pharmacokinetics and pharmacodynamics of metformin were studied in Korean healthy volunteers at fasting state over 10 hours. (omitted)

• Archives of Pharmacal Research
• /
• 제13권1호
• /
• pp.74-77
• /
• 1990

N-(2-Amamantyl)-N-(5-arylhydrazono-6-methyl-4-oxopyrimidin-2-yl) guanidines (IIIa, b), 2-(2-admantyl-amino)-4-amino-s-triazine (IVa) and its 6-chloromethyl derivative (IVb) were prepared by cylization of 1-(2-admantyl) biguanide HCl (I) with ethyl 2-arylhydrazono-3-oxobutyrates (II), ethyl formate and ethyl chloroacetate, respectively. Where 1-(2-admantyl)-3-(4, 5-dioxo-2-imidazolidinylidene)guanidine (V) was used as intermediate for the synthesis of amides (VIIa, b), hydrazide (VIII) and azomethine derivatives (IX, b) of alkyl 2-(2-admantyl-amino)-4-amino-2-triazine-6-carboxylates (VI a, b). The antimicrobial testing of the prepared compounds proved that compound 1Xb was the most active. It showed a marked bacteriostatic effect against Staphylococcus aureus and Bacillus subtilis.

• 한국임상약학회지
• /
• 제25권3호
• /
• pp.131-137
• /
• 2015

Background: The protective effect of metformin against breast cancer is inconclusive. Objective: To evaluate the effect of metformin on breast cancer risk and mortality in patients with type 2 diabetes. Method: A comprehensive literature search was performed for pertinent articles published prior to June 30, 2014, using PubMed and EMBASE. Study heterogeneity was estimated with $I^2$ statistic. The data from the included studies were pooled and weighted by random-effects model. The quality of each included study was assessed on the basis of the 9-star Newcastle-Ottawa Scale and publication bias was evaluated by visual inspection of a funnel plot. Results: Ten studies were included in the meta-analysis of the association of metformin and breast cancer risk. By synthesizing the data from the studies, the pooled odds ratio (OR) was 0.72 (95% CI: 0.59, 0.87) (p = 0.0005). Three cohort studies were included for meta-analysis of the association between metformin and breast cancer-related mortality. Metformin was associated with a significant decrease in mortality (Risk ratio: 0.68; 95% CI: 0.51, 0.90, p = 0.007). Conclusion: The present meta-analysis suggests that metformin appears to be associated with a lower risk of breast cancer incidence and mortality in patients with type 2 diabetes.

• 한국미생물·생명공학회지
• /
• 제40권3호
• /
• pp.180-185
• /
• 2012

Type 2 Diabetes Mellitus, a chronic metabolic disorder which results from a high blood glucose level, is one of the most prevalent and costly diseases of our time. Considering increasing rates of obesity and the aging population in Korea, the number of diabetic patients is likely to rise rapidly in the future. There are five conventional diabetic drugs which work through different mechanisms; sulfonylureas, biguanide, meglitinide, alpha-glucosidase inhibitors, and thiazolidinedione. Although they all have antidiabetic effects, some side effects such as hypoglycemia, weight gain and gastrointestinal intolerance are associated with them. Incretin based therapies, utilizing glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have a lower risk of adverse side effects, have recently been introduced. At present PPAR-targeting drugs are being actively developed. In this research review, particular emphasis has been placed on the current trends and possible biological targets for the new generation of antidiabetic drugs.